In LLC tumor models, a curcumin-based treatment strategy was shown to reduce the frequency and absolute number of MDSCs in the spleen and tumor tissues, significantly reduce IL-6 levels in tumor tissues and the serum, weaken the Arg-1 expression level and ROS production in MDSCs purified from tumor tissue in vivo, and promote the expression of the maturation markers F4/80, MHCII, CD11c, and CD80 on MDSCs in tumors. This evidence concerns the gene ARG1 and neoplasm.